Danon disease is a rare genetic disorder whose complications can ultimately cause heart failure, and for male patients, frequent death.
Rocket Pharmaceuticals, Inc. RCKT incurred a loss of 71 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 78 cents. In the year-ago quarter, the company...
Rocket Pharmaceuticals: Q3 Earnings Snapshot
Rocket Pharmaceuticals: Q2 Earnings Snapshot
The S&P 500 Index ($SPX ) (SPY ) today is down -0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.29%. Stock indexes today are lower...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.33%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.35%. Stock indexes today are moderately...
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.
Its near-term risks are subtle but bigger than their flying stock price might indicate.
Although Rocket Pharmaceuticals lived up to its name on Wednesday due to an encouraging clinical trial development, the big dogs have some questions about RCKT stock.
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.